Arrowhead Pharmaceuticals, Inc. (ARWR): EBITDA
$120.55M
Year ended 2025-09-30
-$202.34M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | $120.55M | n/m | 2025-11-25, From 2024-10-01 |
| 2024-09-30 | -$584.18M | n/m | 2025-11-25, From 2023-10-01 |
| 2023-09-30 | -$194.30M | n/m | 2025-11-25, From 2022-10-01 |
| 2022-09-30 | -$169.81M | n/m | 2024-11-26, From 2021-10-01 |
| 2021-09-30 | -$142.44M | n/m | 2023-11-29, From 2020-10-01 |
| 2020-09-30 | -$88.96M | n/m | 2022-11-28, From 2019-10-01 |
| 2019-09-30 | $63.89M | n/c | 2021-11-22, From 2018-10-01 |
| 2018-09-30 | -$52.94M | n/m | 2020-11-23, From 2017-10-01 |
| 2017-09-30 | -$34.01M | n/a | 2019-11-25, From 2016-10-01 |
| No annual figure between 2014-09-30 and 2017-09-30. | |||
| 2014-09-30 | -$51.93M | n/m | 2016-12-14, From 2013-10-01 |
| 2013-09-30 | -$22.84M | n/m | 2015-12-14, From 2012-10-01 |
| 2012-09-30 | -$19.34M | n/m | 2014-11-25, From 2011-10-01 |
| 2011-09-30 | -$9.56M | n/m | 2012-12-28, From 2010-10-01 |
| 2010-09-30 | -$5.56M | n/a | 2011-12-20, From 2009-10-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 2025-09-30 | $120.55M | n/m |
| ANI Pharmaceuticals Inc (ANIP) | 2025-12-31 | $202.51M | +196.4% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $45.95M | -66.6% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $195.90M | n/m |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $110.21M | n/m |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $29.28M | -81.9% |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2025-12-31 | -$298.59M | n/m |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $78.78M | n/m |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | -$500.00M | n/m |
Compare ARWR, ANIP, CORT, EBS side by side · Screen every company in Pharmaceutical Preparations ↗